

STUDY ELIGIBILITY FORM

FACTORS	ASSESSMENT	COMMENTS
TYPE OF STUDY		
1. Is the study described as observational (cohort, case control, or cross-sectional) study or randomized controlled trial?	Yes Unclear No Exclude	
PARTICIPANTS		
2. Were participants treated with warfarin?	Yes Unclear No Exclude	
3. Were participants of the postspecified age? NB: Please answer „Yes“, If mix age participants i.e. both <=18 years and >18 years are included and state it as comments. No: If only > 18 years.	Yes Unclear No Exclude	Subgroups available?
Genotyping		
4. Were study participants performed SNPs analysis (CYP2C9, VKORC1, or CYP4F2)?	Yes Unclear No Exclude	
OUTCOMES		
5. Did the study report warfarin maintenance dose?	Yes Unclear No Exclude	
FINAL DECISION 1 X "No" = EXCLUDE 1 X "Unclear" = UNCLEAR	Include Unclear Exclude	

STUDY CHARACTERISTICS			
Sample size	Randomized / Recruited / Number ()		
Number of excluded patients	No / NA / Yes (N=)		
Recruitment method	consecutive inclusion / N/A / Others ()		
Setting	in-patient / out-patient / unclear / NR		
Location of trial			
Dates of Recruitment	From (Day/Month/Year) To (Day/Month/Year)		
Study Design	RCT / Cohort / Cross-sectional / Others Single center / Multicenter trial: international / national / # centers: __ Prospective / Retrospective		
Aim of study	Warfarin dose requirement / Time to stable dose ADE (e.g. severe bleeding or thrombosis) Others ()		
Funding	Industry / Public / Mixed (industry supported: drug / data management / travel / salary / other unclear / NR		
Conflict of interest statement	Yes <input type="checkbox"/> / No <input type="checkbox"/> / NR <input type="checkbox"/>		
Tested SNPs	CYP2C9	VKORC1	CYP4F2
	Yes <input type="checkbox"/> / No <input type="checkbox"/> *2 (rs1799853) *3 (rs1057910) Others () P<0.05? Yes <input type="checkbox"/> / No <input type="checkbox"/> / NA <input type="checkbox"/>	Yes <input type="checkbox"/> / No <input type="checkbox"/> G1639A (rs9923231) C1173T (rs9934438) Others () P<0.05? Yes <input type="checkbox"/> / No <input type="checkbox"/> / NA <input type="checkbox"/>	Yes <input type="checkbox"/> / No <input type="checkbox"/> V433M (rs2108622) Others () P<0.05 Yes <input type="checkbox"/> / No <input type="checkbox"/> / NA <input type="checkbox"/>
Definition of warfarin maintenance dose			
Comments			

PATIENTS CHARACTERISTICS	
Age (year)	Mean () / Median () / Mode () SD () / SE () / Minimum () / Maximum () 1st Quartile () / 3rd Quartile () 95% CI inferior () / 95% CI superior ()
Gender (Number)	Male () / Female ()
Race (Number)	Caucasian () / Asian () African () / Others () Comment:
Concomitant drug information	NA / Available
Diet information	NA / Available
Indication for warfarin	Congenital or aquired heart disease (N=) Fontan (N=) / Heart valve replacement (N=) Cardiomyopathy (N=) / Coronary aneurysms (N=) Pulmonary hypertension (N=) Other cardiac disorders (N= ,) Non-Cardiac disorder (N=) Deep vein thrombosis (N=) / Stroke (N=) Other conditions (N= ,)
Target INR range	NA / Available
Comments	

OUTCOME MEASUREMENT (Warfarin Maintenance dose)										
	Data available	Sample number	Unit	Mean	Median	SD	MIN	MAX	95% CI Inferior	95% CI Superior
CYP2C9										
	*1/*1									
	*1/*2									
	*1/*3									
	*2/*3									
	*2/*2									
	*3/*3									
	Variant Hetrozygus									
	Variant Homozygus									
	Variant (any *2 or*3)									
VKORC1										
	1639-GG									
	1639-GA									
	1639-AA									
	1639-GA or -GG									
	1173-CC									
	1173-CT									
	1173-TT									
	1173-CT or -TT									
CYP4F2										
	V433M, TT									
	V433M, CT									
	V433M, CC									
	V433M, CT or CC									

Newcastle-Ottawa Quality Assessment Scale for Cohort Studies

Selection

- 1) Representativeness of the variant genotypes in each SNP
 - a) truly representative in the community ☆
 - b) somewhat representative in the community ☆
 - c) selected group of users
 - d) no description of the derivation of the cohort
- 2) Selection of the wild genotype in each SNP
 - a) drawn from the same community as the exposed cohort ☆
 - b) drawn from a different source
 - c) no description of the derivation of the non exposed cohort
- 3) Ascertainment of genotype
 - a) secure record ☆
 - b) structured interview ☆
 - c) written self report
 - d) no description
- 4) Demonstration of genotyping was not present at start of study
 - a) yes ☆
 - b) no

Comparability

- 1) Comparability of cohorts on the basis of the design or analysis
 - a) study controls for body size or age ☆
 - b) study controls for any additional factor (e.g. target INR range, indication, or diet) ☆

Outcome

- 1) Assessment of outcome
 - a) independent blind assessment ☆
 - b) record linkage ☆
 - c) self report
 - d) no description
- 2) Was follow-up long enough for outcomes to occur
 - a) yes (more than 1 month of stable warfarin control) ☆
 - b) no
- 3) Adequacy of follow up of cohorts
 - a) complete follow up - all subjects accounted for at least 1 months ☆
 - b) subjects lost to follow up unlikely to introduce bias - small number lost <10 % ☆
 - c) follow up rate < 90% and no description of those lost
 - d) no statement

Total number of stars: stars